Full Text
POSB125 The Impact of Discounting on the Cost Effectiveness of Tisagenlecleucel for Relapsed/Refractory Acute Lymphoblastic Leukaemia

Abstract

Authors

N Carey L Mccullagh M Barry

Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×